Trial Profile
A Phase I/Ib, Randomised, Double-blind, Placebo-controlled Study in Healthy Postmenopausal and Pre-menopausal Women to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics of Single and Multiple Ascending Oral Doses of FOR-6219 and the Pharmacodynamics of Multiple Oral Doses of FOR-6219
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs FOR-6219 (Primary)
- Indications Endometriosis
- Focus Adverse reactions; First in man
- Sponsors Forendo Pharma
- 03 Mar 2021 Results published in a Forendo Pharma media release.
- 03 Aug 2020 Planned End Date changed from 30 Jun 2020 to 31 Dec 2020.
- 03 Aug 2020 Planned primary completion date changed from 30 Jun 2020 to 31 Dec 2020.